Belenos Biosciences is a clinical-stage biotech developing immunotherapies for chronic inflammatory diseases, including asthma, chronic obstructive pulmonary disease, and atopic dermatitis. Founded in 2024, the…
In November 2025, Pfizer finalized its $10 billion acquisition of Metsera, a transaction that highlighted the company’s strategic push into the rapidly expanding obesity treatment…
UK-based Charm Therapeutics has closed an $80 million Series B round as it seeks to establish a foothold in a rapidly expanding and increasingly competitive…
Corvus Pharmaceuticals, founded in 2014, develops targeted therapies designed to modulate the immune system. Its pipeline includes Soquelitinib, Ciforadenant, and Mupadolimab. These programs focus on…
Helicore Biopharma has emerged as a notable player in obesity therapeutics research through its work on neutralizing the glucose-dependent insulinotropic polypeptide, or GIP. The company…
ARS Pharmaceuticals launched neffy in November 2025, introducing the first nasal treatment for anaphylaxis approved by the FDA. The product delivers a single dose of…
BostonGene was recently recognized with the “AI-based Drug Discovery Solution of the Year” award in the 8th annual AI Breakthrough Awards program, which drew more…
FemTech, a term coined in 2016, spans technologies built specifically for female biology. This growing field of technology focused on women’s health includes a wide…
On July 18, 2025, Sanofi officially finalized its $9.1 billion acquisition of Blueprint Medicines, a deal aimed at expanding its immunology portfolio and strengthening its…
Cosette Pharmaceuticals’ planned $430 million acquisition of Australia-based Mayne Pharma was positioned to strengthen its position in women’s health and dermatology. The proposed deal announced…
Insilico Medicine, an emerging AI-driven biotech startup, is gaining attention in the TechBio space for its use of generative AI to transform drug discovery and…
Novo Nordisk has gained a strong position in the global market for weight management drugs, primarily due to the widespread use of its semaglutide-based drugs—Ozempic,…
HistoSonics’ Edison® System, an ultrasound-based tool that employs histotripsy to non-invasively destroy tumours without relying on surgery or radiation, is expected to become available to…
On May 5, 2025, Firefly Neuroscience announced its acquisition of Evoke Neuroscience in a $6 million deal aimed at strengthening its Brain Network Analytics (BNA™)…
Nanotherapeutics is a transformative field in modern medicine, utilizing nanotechnology to tackle some of the most challenging issues in drug delivery, gene therapy, and regenerative…
January 28, 2025
Sign up to get access
"*" indicates required fields
Sign up to get access
Please provide accurate and verifiable contact information to ensure proper use of our materials and prevent misuse. Thank you for your understanding!
